All In Biotech

Drug Trial Radar · NCT07682129

Long-Term Extension Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon Skipping to Evaluate the Safety and Efficacy of Endosomal Escape Vehicle Phosphorodiamidate Morpholino Oligomer Platform Products (ELEVATE-LTE)

A Phase 2, Open-Label Long-Term Extension Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon Skipping to Assess the Long-Term Safety, Tolerability, Pharmacokinetics, and Efficacy of Endosomal Escape Vehicle Phosphorodiamidate Morpholino Oligomer Platform Products (ELEVATE-LTE)

Last checked: Nov 20, 2026Latest source record: Jul 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

80

Planned (sponsor's estimate)

Start

Aug 2026

Primary completion

Mar 2032

Study completion Mar 2032

Sponsor

Lead sponsor
Entrada Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Jul 2, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 4 years, up to 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a study of investigational medicines ENTR-601-44 and ENTR-601-45 designed to evaluate the long-term safety and tolerability of study drugs in participants with Duchenne muscular dystrophy (DMD). The investigational medicines are currently being investigated in multiple ascending dose parent studies. After participants complete their respective parent study, there is a need to understand the effects of long-term administration of ENTR-601-44 and ENTR-601-45. Participants enrolling in this study will begin this long-term extension (LTE) study at the dose level they received upon completion of the parent study with possible dose escalation in the LTE study based on emerging safety and efficacy data from the parent studies. Participants will: * Receive study treatment in the form of multiple intravenous (IV) infusions (slow injections) into a vein over the course of several weeks * Visit the clinic regularly for checkups and tests such as: blood and urine tests, physical examinations, questionnaires, and excersice tests. Participants will have a muscle biopsy at the beginning of their participation and after their last dose to allow researchers to compare whether there have been changes in the muscle as a results of the study drug. Participants are allowed to continue receiving their standard of care therapy for DMD during the study, as long as their health remains stable.

Conditions

  • Duchenne Muscular Dystrophy (DMD)

Interventions

  • ENTR-601-44Drug

    ENTR-601-44 intravenous infusion

  • ENTR-601-45Drug

    ENTR-601-45 intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with Treatment Emergent Adverse Events (TEAEs) according to study protocol (Part A and OL Period)Time frame: From baseline through End of Study (up to 2 years).

Locations

17 sites in 5 countries. Site status is shown where the registry gives one.

  • University Hospital Gent

    Ghent, Belgium

  • UZ Leuven

    Leuven, Belgium

  • Centre Hospitalier Régional de la Citadelle

    Liège, Belgium

  • IRCCS Ospedale San Raffaele

    Milan, Italy

  • Fondazione Serena Onlus - Centro Clinico NeMO Milano

    Milan, Italy

  • Fondazione Policlinico Universitario A. Gemelli IRCCS - Universita Cattolica del Sacro Cuore

    Roma, Italy

  • Ospedale Pediatrico Bambino Gesu

    Rome, Italy

  • Leids Universitair Medisch Centrum

    Leiden, Netherlands

  • Stichting Radboud Universitair Medisch Centrum

    Nijmegen, Netherlands

  • Hospital Universitario Vall d'Hebron

    Barcelona, Spain

  • Hospital Sant Joan de Deu

    Barcelona, Spain

  • Leeds General Infirmary

    Leeds, United Kingdom

  • Alder Hey Children's NHS Foundation Trust

    Liverpool, United Kingdom

  • Great Ormond Street Hospital for Children

    London, United Kingdom

  • Royal Manchester Children's Hospital

    Manchester, United Kingdom

  • Freeman Hospital

    Newcastle upon Tyne, United Kingdom

  • Oxford University Hospitals NHS Foundation Trust

    Oxford, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.